Seborrheic dermatitis-like eruption following interleukin-2 administration.
We describe a 72-year-old man suffering from renal cell carcinoma with lung metastases who developed scaly erythema on his face after the administration of recombinant interleukin-2 (rIL-2). A skin biopsy revealed intraepidermal and superficial perivascular infiltrate of mononuclear cells that were mainly composed of CD3 positive T-cells. There have been two cases of seborrheic dermatitis-like eruption induced by rIL-2. However, neither of them had histopathological evaluation. To our knowledge, this is the first case of seborrheic dermatitis-like eruption following rIL-2 administration whose histopathological investigations were performed.
Kawakami
Yoshio
Y
Nakamura-Wakatsuki
Taeko
T
Yamamoto
Toshiyuki
T
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D012628:Dermatitis, Seborrheic / Q000209:etiology / Q000473:pathology*; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology*; D005148:Facial Dermatoses / Q000209:etiology / Q000473:pathology*; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male
D000970:Antineoplastic Agents; D007376:Interleukin-2